H2020Individual fellowship2019–2021

ProDelivery · High Throughput Synthesis of Polymeric Vesicles for Protein Delivery

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2019-09-01 → 2021-08-31
EU contribution
€224,934
Participants
1
Scheme
MSCA-IF-EF-ST

Lines connect the coordinator with its partners.

Results in brief

High Throughput Synthesis of Polymeric Vesicles for Protein Delivery

Although protein-based therapeutics have become increasingly prevalent in the clinic due to their high selectivity, their overall potency has been hampered by their instability in vivo. As a result, conventional drugs such as chemotherapeutics though generally possessing lower selectivity (and hence, more significant side effects), are still commonly employed as first line therapeutics. To improve the stability and hence potency of protein therapeutics, one approach is to develop nanoformulations encapsulating and protecting the sensitive therapeutics during delivery to the target site. The overall goal of ProDelivery has been to develop a chemical synthetic platform enabling the efficient synthesis of proteins encapsulated within polymeric nanoparticles known as polymersomes. A key aspect of the developed platform has been the optimisation of ultralow volume chemistry in order to allow for cost-efficient nanoformulation of expensive protein therapeutics. This enables greater chemical space to be explored for screening formulations and also allows a broader range of protein therapeutics to be readily accessed in the academic environment. Using the developed protein-loaded polymersome formulations, the proteins retain their activity after encapsulation, the polymersomes themselves are not cytotoxic over a broad range of concentrations and the polymersome membrane can protect the encapsulated cargo from thermal, proteolytic and intracellular stresses over prolonged periods of time. Overall, these results establish the developed chemical platform as a highly promising proof-of-concept for the stabilisation, screening and delivery of clinically relevant protein therapeutics. The multidisciplinary nature of this highly ambitious project was strongly supported by its localisation within the world-renowned Stevens Group at Imperial College London. The diverse nature of the project required input from a number of personnel within the Group with research backgrounds across chemistry, materials science, spectroscopy and cell biology and was crucial to meeting project outcomes. Ongoing collaborations which have been established as a result of this fellowship will continue to drive this work towards future applications.

Data: CORDIS, © European Union

Project objective

The delivery of therapeutic protein drugs in biological environments is hampered by their relative sensitivity to a broad range of physical and chemical factors. To address this loss in therapeutic efficacy, chemical formulations using polymers as stabilising agents have been proposed. Unfortunately, systematic studies of these formulations are often limited in scope owing to the relatively high cost of protein therapeutics as well as restrictions on the types of chemical transformations that can be performed without loss of protein activity. Hosted within Prof. Molly Stevens' labs at Imperial College London (www.stevensgroup.org, recognised by >25 major awards), the overall goal of this proposal is therefore to develop a versatile chemical synthetic platform enabling the efficient synthesis of protein encapsulated polymeric vesicles. This will be achieved by exploiting low volume, high throughput polymer chemistry to allow for a cost and time efficient study of vesicle structure-activity relationships in the context of protein stabilisation and efficacious delivery of proteins to biological targets. The proposed combinatorial approach is highly versatile and can, in principle, be applied for the study of a broad range of proteins or other biologically relevant therapeutics. The versatility and translation potential of this project will be fully evaluated within the excellent infrastructure available within the Stevens Group.

Original text from CORDIS.

Participants

  • IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE · LondonCoordinatorUnited Kingdom

Links

Data: CORDIS, © European Union